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Background: Alterations of mTOR gene expression have been implicated in the pathogenesis of endometrioid
endometrial cancer however only few studies explored the cause of increased mTOR activation in this malignancy.
miRNAs are small, noncoding RNAs, which were proven to regulated gene expression at the posttranscriptional
level. The study aimed to explore deregulation of miRNAs targeting mTOR kinase (miR-99a, miR-100 and miR-199b)
as a possible cause of its altered expression in EEC tissues. In addition expression of the three miRNAs was
investigated in plasma of EEC patients and was assessed in terms of diagnostic and prognostic utility.
Methods: We investigated expression of mTOR kinase transcripts in 46 fresh tissue samples. Expression of miR-99a,
miR-100 and miR-199b was investigated in the same group of fresh samples, and in additional 58 FFPE sections as
well as in 48 plasma samples using qPCR. Relative quantification was performed using experimentally validated
endogenous controls.
Results: mTOR kinase expression was increased in EEC tissues and was accompanied by decreased expression of all
three miRNAs. Down-regulation of the investigated miRNAs was discovered in plasma of EEC patients and miRNA
signatures classified EEC tissues (miR-99a/miR-100/miR-199b) and plasma (miR-99a/miR-199b) samples with higher
accuracy in comparison to single miRNAs. We also revealed that miR-100 was an independent prognostic marker of
overall survival.
Conclusions: We conclude that increased expression of mTOR kinase coexists with down-regulation of its targeting
miRNAs, which could suggest a new mechanism of mTOR pathway alterations in EEC. In addition, our findings
implicate that miRNA signatures can be considered promising biomarkers for early detection and prognosis of
endometrioid endometrial carcinoma.
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Endometrial cancer is the most common malignant
tumor of the female reproductive tract and the fourth
most often occurring malignancy in the female popula-
tion of developed countries [1,2]. The incidence of endo-
metrial cancer has increased in the Great Britain, as it
was reported by Evans et al. [3]. Similar trend was also
observed in Poland basing on the data provided by Pol-
ish Cancer Registry [4]. Most endometrial cancers are
diagnosed in early clinical stages and can be managed
surgically with good results, however there is still a
number of cases with bad prognosis due to lack of ef-
fective treatment for advanced, recurrent or dissemi-
nated disease. Approximately 80% of endometrial
cancers are of endometrioid histology [5]. Etiology of
endometrioid endometrial tumors has been connected
with alteration of several genes [6,7]. In particular altera-
tions of PTEN (phosphatase and tensin homologue)
gene and its product were widely investigated and loss
of PTEN activity was proven to induce increased AKT
(v-akt murine thymoma viral oncogene homolog; rac-
beta serine/threonine protein kinase) and mTOR activity
[8-10].
mTOR (mechanistic target of rapamycin) gene is
located on chromosome 1 (locus 1p36.2) and encodes
for the serine/threonine kinase, which plays a role in cel-
lular response to various stress factors including
decreased ATP level, hypoxia and DNA damage. mTOR
is involved in the regulation of translation process, cellu-
lar proliferation and differentiation [11,12]. It is of par-
ticular interest that mTOR kinase, which integrates
several cellular pathways activated in the response to
changes in ATP and growth factors levels as well as
those responsible for cell growth and proliferation,
becomes deregulated in many malignant diseases includ-
ing endometrial cancer [13-16]. It has been proven that
it is activated via AKT phosphorylation both directly
and indirectly through inactivation of TSC2 (tuberous
sclerosis complex 2) [17]. A negative regulation of
mTOR activity involves AMPK (5’-AMP-activated pro-
tein kinase), which inhibits mTOR actions through
phosphorylation and activation of TSC1/TSC2 complex
[18,19]. Increased expression and activity of mTOR
kinase in endometrial cancer has been connected with
the loss of PTEN, LKB1 (Liver Kinase B1) and TSC2
activity as well as increased expression of Phospholip-
ase D1 [20]. Nevertheless, such alterations were not
uniformly reported in all EEC cases therefore other
mechanisms could be involved in the regulation of
mTOR pathway activity including posttranscriptional
regulation of mTOR expression, which involves micro-
RNAs (miRNAs). miRNAs are small, non-coding RNA
molecules composed of 19 to 25 nucleotides which
were proven to regulate gene expression duringposttranscriptional stages [21]. miRNAs play important
roles in development, cell proliferation and differenti-
ation as well as cell cycle control. Several miRNAs
were also associated with the pathogenesis of various
malignancies including endometrial cancer [22]. Guo
et al. have recently proven that in mammalian cells
miRNAs act predominantly through decreasing target
mRNA levels [23]. Therefore down-regulation of miR-
NAs targeting genes involved in carcinogenesis is likely
to favor initiation of malignant transformation. Altera-
tions of genes, which are upstream to mTOR and
could be responsible for its activation, are not uni-
formly present in all EEC cases [5]. Therefore in the
presented study we aimed to assess mTOR kinase
mRNA levels and to explore possible association be-
tween altered expression of mTOR kinase transcripts
and its targeting miRNAs, miR-99a, miR-100 and miR-
199b, which were chosen basing on the three open-
source in silico algorithms (Target Scan, DIANA
microT v. 3.0, miRanda). Expression of the three miR-
NAs was also investigated in plasma of EEC patients




Altogether one hundred and twenty two patients were
included in the study. Patients were hospitalized in
gynecological departments of Medical University of Lub-
lin (Poland) and Ospedale Sacro Cuore Don Calabria
(Negrar, Italy). Study encompassed 46 tissue samples
and 58 formalin-fixed paraffin-embedded specimens as
well as 48 blood samples. Study design was revised and
approved by Medical University of Lublin Ethical Com-
mittee and informed consent was obtained from each
study participant. The EEC group consisted of 77
patients: 73 were included in tissue part of the study,
whereas material obtained from the remaining four was
used only for miRNA expression analysis in plasma.
Control group for the tissue part of the study included
31 participants operated on due to benign gynecological
pathologies not connected with endometrium and con-
trol group for the plasma part of the study included 14
women with no previous history of cancer or endomet-
rial pathology. All patients with EEC were submitted to
total hysterectomy and bilateral oophorectomy and were
subsequently treated by radiotherapy and/or chemother-
apy according to FIGO guidelines. Lymphadenectomy
was performed in 44 patients (57%). None of the
patients had received neoadiuvant therapy. 2009 revised
FIGO classification was used to determine clinical stage
of the disease [24]. Table 1 presents detailed characteris-
tics of the patients included in the study. 85.3% of
patients with EEC were postmenopausal, whereas most





Average age (years) 62.8 years ± 10.14* 44.78 ± 7.19*































* T-test, p < 0.001.
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(81.6%). The plasma control group comprised of equal
numbers of pre- and postmenopausal cases.
Samples
Fresh tissues were sampled within 15 minutes from exci-
sion of the uterus. Tissues were immediately stored in
RNAlater (Ambion) and incubated in this solution for
24 hours in 4°C. Tissues were then stored in -80°C until
RNA isolation.
FFPE tissues used for the study were fixed with 10%
formalin and stored for maximum 10 years. All the ori-
ginal hematotoxylin and eosin (H&E)-stained sections
were reviewed by a gynecopathologist (A.P.). EEC speci-
mens were classified, according to the 2002 WHO classi-
fication in G1, G2 or G3. Specimens containing at least
70% of cancer cells, were selected and micro dissected.Samples of the normal endometrium (NE) included
both proliferative and secretory phase epithelium.
All blood samples were collected from antecubital vein
using closed blood collection system (S-Monovette
(EDTA), Sarstedt) and centrifuged for 15 minutes
(3200 rpm, 19°C). Plasma was collected, aliquoted and
stored in –80°C.RNA isolation
40 to 80 mg of macro dissected tissues stored in RNAla-
ter was homogenized in a rotor -stator homogenizer and
RNA was isolated using mirVANATM miRNA Isolation
Kit (Ambion) according to manufacturer’s protocol.
RNA isolation from FFPE tissues was performed using
Recover All™ Total Nucleic Acid Isolation Kit for FFPE
Tissues (Ambion) according to the protocol provided by
the manufacturer. As suggested in the protocol, 10 μm
FFPE sections were used for isolation procedure. RNA
isolated from tissues underwent DNase treatment using
Turbo DNAase Kit (Ambion).
Isolation of RNA from plasma was performed using
mirVANATM PARIS Kit (Ambion) and 400 mL of
plasma. 5 fmol/μl of each of the following synthetic Cae-
norhabditis elegans oligonucleotides : cel-miR-39, cel-
miR-54, cel-miR-238 was spiked into plasma sample
after addition of 2xDenaturating Solution. From that
point isolation was performed according to manufac-
turer’s protocol. Elution was performed with 52.5 μl of
RNase, DNase-free water. Isolation of RNA from plasma
was conducted in duplicates. RNA was stored in –80°C.
Concentration and purity of RNA was inspected using
spectrophotometer (Biophotometer with Hellma Tray
Cell, Eppendorf ) and RNA integrity was checked using
Bioanalyzer 2100 (Agilent Technologies Inc.) and Agi-
lent RNA Nano kit. In case of RNA isolated from fresh
frozen tissues only samples with RIN≥ 6 were used in
downstream applications. In case of RNA extracted from
FFPE the average RIN was 3.45. 260/280 ratio of all tis-
sue samples ranged between 1.8 - 2.2.Reverse transcription of total RNA
Total RNA (500 ng) was reverse transcribed in tripli-
cates using Precision nanoScript Reverse Transcription
kit (Primer Design) according to manufacturer protocol.
Briefly, a mix of 9 μl of RNA o 1 μl of random nonamers
was incubated in 65°C for 5 min. Then the mixture was
combined with 2 μl nanoScipt buffer 10x, 1 μl 10 mM
nucleotides, 2 μl 100 mM DTT, 1 μl reverse trancriptase
and 4 μl water. Reactions were then incubated in 25°C
for 5 min, in 55°C for 20 min and in 75°C for 15 min.
Reactions were carried in Master cycler ep gradient S
(Eppendorf) and stored in –20°C.
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Amplification of mTOR, PTEN and three reference genes
(SDHA, UBC, CYC1) was performed in 20 μL reactions.
Each reaction consisted of: 1 μL 20x TaqManW Gene Ex-
pression Assay (mTOR Hs00234508, PTEN Hs02621230_s1,
SDHA Hs00188166_m1, UBC Hs00824723_m1, CYC1
Hs00357717_m1, Applied Bios stems), 4 μL cDNA (50 ng),
10 μL 2x TaqManW Gene Expression Master Mix (Applied
Bios stems) and 5 μL water. Reactions were carried out in
duplicates in Rotor Gene 6000 2-plex HRM thermo cycler
(Corbett Research) using the following protocol: 95°C for
10 min and 45 cycles of 95°C for 15 sec/55°C for 60 sec.
Cq values were determined with the threshold value of
0.03 and automatically defined baseline.
miRNA Reverse transcription and real-time qPCR
RNA isolated from tissues was reverse transcribed in
7.5 μl reactions, which consisted of 3.5 μL RT Master
Mix (0.75 μL 10 x RT Buffer, 0.075 μL 100 mM dNTPs,
0.5 μL MultiscribeTM Reverse Transcriptase, 0.095 μL
RNase Inhibitor (20U/μL), 2.08 μL nuclease-free water,
1.5 μL of specific starters and 2.5 μL RNA (5 ng). Plasma
RNA was reverse transcribed in 5 μl reactions: 0.5 μL 10
x RT Buffer, 0.05 μL 100 mM dNTPs, 0.33 μL Multiscri-
beTM Reverse Transcriptase, 0.063 μL RNase Inhibitor
(20U/μL), 1.387 μL nuclease-free water, 1 μL specific
starters and 1.67 μL of RNA eluate. RT reactions were
carried out in triplicates using following protocol: 16°C
for 30 min, followed by 42°C for 30 min and 85°C for
5 min in Master cycler ep gradient S (Eppendorf) and
stored in –20°C.
qPCR reactions for miRNA expression analysis were
prepared as follows: 0.5 μL 20x TaqManW MicroRNA
Assay (assay IDs, miR-99a 000435, miR-100 000437,
miR-199b 000500, Applied Bios stems), 4.5 μL RT prod-
uct (dilution 1:15 for tissues and 1:7.5 for plasma), 5 μL
2x TaqManW Universal PCR Master Mix (Applied
Biosystems).
All qPCR reactions were performed in duplicates in
ViiA7 Real–Time PCR System (Applied Biosystems)
using the following PCR protocol: 95°C for 10 min and
45 cycles of 95°C, 15 s/60°C, 60 s. Positive and negative
control reactions as well as inter–plate calibrator (IPC)
reactions were carried out on each plate.
Cq values were determined with the threshold value of
0.2 and automatically defined baseline.
Normalization of qPCR data
Before statistical analysis qPCR data were normalized
with inter-plate calibrators to adjust for run-to-run
differences and corrected for reaction efficiency [25].
Efficiency of each primer/probe sets was determined
by performing standard curve with six-fold dilution of a
pooled cDNA template.Expression of mTOR and PTEN was then further nor-
malized using geometric mean of the expression of three
stable reference genes: SDHA, UBC and CYC1, which
were experimentally chosen from the panel of 12 candi-
date genes. Similarly, tissue miRNA qPCR data were
normalized using geometric mean of the expression of
three experimentally chosen endogenous controls
RNU48, RNU44 and U75. Choice of those specific
snRNA was performed from the panel consisting of 12
non-coding RNAs, which were previously described to
be stably expressed in tissues or were used in endomet-
rial cancer qPCR studies [26-29].
Additional normalization step was implemented in
case of plasma miRNA expression data in order to adjust
for the variation in RNA extraction. Raw data were ini-
tially normalized to expression of three synthetic oligo-
nucleotides matching the sequences of Caenorhabditis
elegans miRNAs: cel-miR-39, cel-miR-54, cel-miR-238
using median normalization procedure as it was previ-
ously described [30,31].
Five experimentally chosen stable endogenous con-
trols: miR-93, miR-26b, miR-192, miR-103a, miR-142-
3p were then used for normalization of plasma miRNA
expression data. Reference miRNAs were chosen from
the panel comprising nine candidate miRNAs (miR-93,
miR-26b, miR-192, miR-103a, miR-142-3p, miR-92a,
miR-638, miR-16 and miR-451), which were suggested
to be highly and stably expressed in plasma [32-35].
Endogenous controls used for both mRNA and miRNA
relative expression studies were chosen using two stat-
istical tools Norm Finder and geNorm and validation
studies were performed in groups consisting of 45 tis-
sue samples and 48 plasma samples [36,37].
Statistical analysis of qPCR data
After normalization data were log transformed. Results
are presented as mean with 95% confidence intervals
(95% CI) or a fold change (FC) with 95% CI.
D’Agostino-Pearson test and Fisher test were used to
assess normal distribution of data and equality of var-
iances, respectively. Comparisons between the groups
were performed with Student t-test (with or without
Welch correction) and ANOVA or with nonparametric
tests (Mann–Whitney and Kruskal-Wallis) depending on
the results of the normality assessment. Spearman coeffi-
cient was applied to determine correlation between
expressions of miRNAs.
Receiver-operating characteristics (ROC) curves were
constructed and sensitivity, specificity as well as positive
and negative predictive values were determined to assess
accuracy of miRNA expression in classifying EEC and
control samples.
Multivariate logistic regression analysis was applied to
inspect if miRNA signatures composed of more than
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between tumor and control samples. χ2 Wald test and
Hosmer-Lemeshow test were used to evaluate regression
models.
Survival analysis was performed using univariate
and multivariate Cox proportional hazard models and
Kaplan-Meier estimator. Survival curves were com-
pared with log-rank test. Level of significance was set
for p≤ 0.05 and all statistical tests were two-sided.
GenEx 5.3.4. (MultiD) and MedCalc (MedCalc Soft-
ware) version 12.2.1. were utilized to perform data
analysis.Results
mTOR kinase and PTEN mRNA expression in EEC tissues
We found an increased expression of mTOR kinase
mRNA in EEC tissues (FC 1.54, 95% CI 1.01-2.36,
p = 0.033) (Figure 1). Comparison of groups distin-
guished based on histological grade, FIGO stage and
myometrial invasion did not revealed any significant
differences. Nevertheless, when compared separately,
G1 samples were not significantly different in com-
parison to control samples in regards to mTOR ex-
pression, whereas in G2 samples or combination of
G2 and G3 samples mTOR kinase transcripts levels
were significantly up-regulated (p = 0.05 and 0.022,
respectively).
Expression of mTOR was also compared between pro-
liferative and secretory endometrium within the control
group and no significant differences were found between
the groups.Figure 1 mTOR gene expression in endometrioid endometrial cancer
presented in the log scale; * p = 0.033.Expression of PTEN mRNA, a negative upstream
regulator of mTOR pathway, was not changed in the
investigated set of EEC tissues (FC 1.38, 95%CI 0.600–
3.040, p = 0.38)miRNAs targeting mTOR kinase are decreased in EEC
tissues
miR-99a, miR-100 and miR-199b were significantly
down-regulated in EEC tissues (Figure 2). The lowest
expression was attributed to miR-199b (FC 3.52, 95%
CI 1.59-7.79, p = 0.002). In addition, its down-
regulation in EEC tissues correlated with advanced
histological grade and was the lowest in G3 samples.
The difference between G2 and G3 samples was signifi-
cant (p = 0.04) and the difference between combined
G1 and G2 samples and G3 was close to statistical sig-
nificance (p = 0.056).
miR-99a was more than threefold decreased (FC 3.29,
95% CI 1.49-7.26, p = 0.007) in EEC tissues. Comparison
between groups distinguished based on histological
grading revealed the lowest miR-99a expression in G3
samples, which was significantly different from G2 sam-
ples (p = 0.047) and combined G1 and G2 samples
(p = 0.029). Neither miR-99a nor miR-199b expression
correlated with other clinic pathological characteristics
including FIGO stage, myometrial invasion, lymph node
metastasis and relapse.
miR-100 was decreased by the factor 2.56 (9% CI 1.27-
5.23, p = 0.02) and no correlation was found between its
expression and clinic pathological characteristics of the
disease.samples (n = 31) and in the control group (n = 15). Values are
Figure 2 Expression of miR-99a, miR-100 and miR-199b in endometrioid endometrial cancer (EEC n= 73) tissue samples in comparison
to control group (NE n= 31). Values are presented in the log scale; * p = 0.007 (miR-99a), * p = 0.02 (miR-100), * p = 0.002 (miR-199b).
Torres et al. BMC Cancer 2012, 12:369 Page 6 of 13
http://www.biomedcentral.com/1471-2407/12/369Decreased expression of three studied miRNAs signifi-
cantly correlated with increased mTOR expression in
EEC tissues (r = -0.36, p = 0.022 for miR-99, r = -0.36,
p = 0.023 for miR-100, r = -0.2, p = 0.023 for miR-199b).
In addition there was a significant and very strong cor-
relation between miR-99a and miR-100 expression, both
in EEC and control samples groups (r = 0.94, p < 0.0001),
whereas no correlation was found between any of the
two miRNAs and miR-199b.
Comparison of miR-99a, miR-100 and miR-199b ex-
pression performed between proliferative and secretoryFigure 3 Expression of miR-99a, miR-100 and miR-199b in endometrio
to control group (NE n= 14). Values are presented in the log scale; * p < 0endometrium within the control group did not reveal
any significant differences.
miRNAs targeting mTOR kinase are up-regulated in
plasma of EEC patients
Expression of all three studied miRNAs was significantly
increased in plasma of EEC patients (Figure 3). The
highest fold change in expression was attributed to miR-
199b, which was almost three times increased (FC 2.89,
95% 1.6-5.23, p = 0.0007). Nearly two-fold increase was
detected in case of miR-99a expression (FC 1.96, 95% CIid endometrial cancer (EEC n= 34) plasma samples in comparison
.0001 (miR-99a), * p = 0.001 (miR-100), * p = 0.0007 (miR-199b).
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regulated (95% CI 1.13-2.42, p = 0.001).
Comparison of groups distinguished based on FIGO
stage (FIGO IA vs. FIGO> IA) revealed significantly
higher expression of miR-99a in plasma of patients with
more advanced disease (p = 0.039, Figure 4). There was
no significant association between plasma expression
levels of the three miRNAs and grade as well as myome-
trial invasion.
Diagnostic and prognostic significance of miR-99a,
miR-100 and miR-199b
Receiver operating characteristic (ROC) curves were
constructed based on miR-99a, miR-100 and miR-199b
expression in tissues and plasma and were used to access
utility of single miRNAs to differentiate between EEC
and control samples. Resulting ROC curves parameters
including AUCs, sensitivity and specificity values and
positive and negative predictive values were presented in
Table 2. Expression of miR-199b yielded the highest area
under curve (AUC) value of 0.704 (95% CI 0.606-0.794,
p = 0.001) in classifying EEC and normal endometrial tis-
sues (Figure 5). The highest AUC value for detection of
EEC plasma samples was attributed to miR-99a (0.810,
95% CI 0.669–0.909, p < 0.0001) (Figure 6). Next, we ap-
plied logistic regression analysis in order to assess, if sig-
natures composed of more than one miRNA
distinguished EEC and control samples with higher ac-
curacy. The values predicted by obtained modelsFigure 4 Expression of miR-99a, miR-100 and miR-199b in endometri
distinguished based on FIGO stage. FIGOIA (n = 17), FIGO> IA (n = 17), N
* p = 0.039, # p < 0.05.belonged to <0, 1 > interval and represented the prob-
ability of EEC. In the applied regression model probabil-
ity values > 0.5 classified samples as malignant. The
model is as follows: p= 1/1 + e-z, where e is a base of nat-
ural logarithm equal to 2.71828. . ., and z is a linear com-
bination of miRNAs expression values (xi) weighted by
the regression coefficients (bi) derived from the multi-
variate regression analysis: z = b0 + b1x1 + b2x2 + . . . +
bnxn [38]. A backward stepwise method revealed that tis-
sue expressions of all three miRNAs were independently
associated with EEC and had significant influence on the
constructed model (p < 0.05). The 3-miRNA signature
demonstrated higher sensitivity and specificity in distin-
guishing between cancer and control tissues samples
(Additional file 1 and Additional file 2) in comparison to
single miRNAs. Similarly, backward logistic regression
method revealed that plasma expressions of two miR-
NAs had significant influence on the model constructed
to distinguish EEC and control plasma samples. The 2-
miRNA signature based on miR-99a and miR-199b ex-
pression in plasma was more accurate in comparison to
single miRNAs, with 88% sensitivity and 93% specificity
(Table 2, Additional file 3 and Additional file 2).
Univariate Cox regression analysis revealed association
between miR-99a (p = 0.034) and miR-100 (p = 0.05)
expression in tissues and overall survival. Moreover,
miR-99a (p = 0.002) and miR-100 (p = 0.005) were the
only independent prognostic markers of overall survival
in a multivariate analysis, which included FIGO stage,oid endometrial cancer (EEC) plasma samples in groups
E, normal endometrium (n = 14). Values are presented in the log scale;
Table 2 Receiver operating characteristics curve (ROC) analysis using tissue and plasma miRNAs expression for
discriminating endometrioid endometrial cancer (EEC) samples
miRNA/miRNA signature AUC
[95% CI]
p Sensitivity Specificity C +PV -PV
Tissues (EEC n= 73, NE n= 31)
miR-99a 0.675
[0.572-0.767]
0.006 0.88 0.5 6.6 81.3 63.6
miR-100 0.652
[0.548-0.746]
0.03 0.86 0.5 6.5 80.8 58.3
miR-199b 0.706
[0.606-0.794]
0.001 0.81 0.71 5.3 87.5 60.6
miR-99a/miR-100/miR-199b 0.774
[0.678-0.853]
<0.0001 0.61 0.89 0.76 93.3 48.1
Plasma (EEC n= 34, NE n = 14)
miR-99a 0.810
[0.669-0.909]
<0.0001 0.76 0.79 1.23 89.3 57.9
miR-100 0.740
[0.592-0.857]
0.001 0.64 0.79 1.5 33.3 92.8
miR-199b 0.786
[0.642-0.892]
0.0002 0.79 0.71 2.48 86.7 58.8
miR-99a/miR-199b 0.903
[0.780-0.970]
<0.0001 0.88 0.93 0.73 96.7 76.5
AUC - area under curve; 95% CI – 95% confidence interval; C - factor; +PV - positive predictive value; -PV - negative predictive value.
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of lymph node metastases (Table 3).
In order to generate Kaplan-Meier curves log trans-
formed normalized Cq values were converted into
discrete variables by splitting the samples into “high”
and “low” expression group using quartile method.
Kaplan-Meier estimation and log rank test confirmed
the association with the overall survival in case of miR-
100 (p = 0.02, HR 0.43, 95% CI 0.222-0.830) and revealed
shorter survival times in a group presenting down-
regulation of miR-100 expression (Figure 7). In case of
miR-99a similar association was observed, though it didFigure 5 Receiver operating characteristics curve (ROC) analysis
using tissue miRNAs expression for discriminating
endometrioid endometrial cancer (EEC) samples (EEC (n= 73)
vs. NE (n = 31). A miRNA signature consisting of three miRNAs
yielded area under curve (AUC), which was higher in comparison to
single miRNAs (0.774, 95% CI 0.678–0.853, p < 0.0001).not reach statistical significance (p = 0.066, HR 0.497,
95% CI 0.252-0.980).Discussion
Several studies reported increased expression of mTOR
protein and its phosphorylated form (p-mTOR) in endo-
metrial cancer tissues and cell lines. Study by Darb-
Eshafani et al. was one of the first to describe activation
of mTOR pathway in a set of human endometrial cancer
tissues [16]. Authors found that the activation occurredFigure 6 Receiver operating characteristics curve (ROC) analysis
using plasma miRNAs expression for discriminating
endometrioid endometrial cancer (EEC) samples. A miRNA
signature consisting of two miRNAs yielded area under curve (AUC),
which was higher in comparison to single miRNAs (0.903, 95% CI
0.780–0.970, p < 0.0001, EEC (n = 34) vs. NE (n = 14).
Table 3 Univariate and multivariate analyses of overall survival predictors for patients with EEC
Univariate analysis Multivariate analysis
Exp(b) 95% CI p Exp(b) 95% CI p
FIGO* 2.583 1.352–4.937 0.004 2.938 0.419 –20.579 0.280
Grade** 1.358 0.685–2.689 0.383 0.526 0.109–2.539 0.426
Nodes 3.129 1.393–7.024 0.006 4.368 0.835–22.849 0.082
Myometrial invasion 0.536 0.272–1.054 0.072 1.454 0.394–5.369 0.576
miR-99a 0.806 0.656–0.989 0.034 0.283 0.129–0.622 0.002
miR-100 0.813 0.657–1.007 0.05 2.940 1.386–6.234 0.005
miR-199b 0.807 0.644–1.012 0.065 0.755 0.485–1.175 0.216
*FIGO - I vs. II-IV; ** G1-G2 vs. G3; Exp(b) hazard coefficient, 95% CI – 95% confidence interval.
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Similar observation was made by Lu et al., who observed
mTOR pathway activation in primary tumors and endo-
metrial cancer cell lines, which was associated with
decreased expression of mTOR upstream regulators like
TSC2, LKB1 and PTEN [39]. In line with those studies
Li et al. reported on activation of mTOR pathway in
HEC-1A and Ishikawa cell lines, and found increased ex-
pression of mTOR mRNA and higher expression of its
downstream substrates in PTEN-deficient Ishikawa cell
line [40]. Yoshida et al. pointed at nuclear localization of
p-mTOR as an important indicator of poor prognosis
and tumor progression, whereas most other authors
reported cytoplasmic localization of that kinase [40-42].
A number of studies linked mTOR pathway activation
with loss of PTEN and increased AKT expression
[39,42]. However Mori et al. did not observe any correl-
ation between expression of phosphorylated AKT and
PTEN mutations and expression of its downstream
effectors including p-mTOR [43]. Moreover, in the study
performed by Yoshida et al. there was no association be-
tween activated AKT and p-mTOR expression alongFigure 7 Kaplan-Meier overall survival curve for patients with
endometrioid endometrial cancer (EEC) based on miR-100
expression. Red line – values above median, blue line – values
below median; HR 0.43, 95% CI 0.222–0.830, p = 0.02.with no correlation between AKT expression and cancer
progression or outcome [41]. In accordance with those
findings Darb-Esfahani et al. observed activation of
mTOR in PTEN willed-type cells, in the absence of acti-
vated AKT [16].
Basing on the literature indicating mTOR pathway ac-
tivation in endometrial tumors several mTOR inhibitors
have been studied in this cancer [44,45]. Interestingly in
the recent, phase II study of temsirolimus in manage-
ment of patients with recurrent or metastatic endomet-
rial cancer mTOR inhibition did not correlate with
PTEN status. In addition authors did not found any
relation between expression of phosphorylated AKT,
p-mTOR, or phosphorylated S6 and response to treat-
ment or disease progression [46].
Taken together such observations suggest that alterna-
tive mechanisms, not related to PTEN/AKT alterations,
could play a role in mTOR pathway activation. Based on
that assumption we hypothesized that increased expres-
sion of mTOR kinase could be caused by alterations in
posttranscriptional phases of its biogenesis, which might
occur due to disturbed expression of its targeting
miRNAs.
Using a quantitive PCR and three experimentally vali-
dated endogenous controls we found that mTOR tran-
scripts level was elevated in EEC tissues. In addition we
did not observe significant alteration of PTEN mRNA
expression, which is a negative upstream regulator of
mTOR kinase pathway. Such observation is in accord-
ance with the previous study reporting increased expres-
sion of mTOR transcripts and protein in endometrial
cancer cell lines as well as with findings presented by
Yoshida et al. and Mori et al. [40,41,43]. In addition we
have also observed that mTOR mRNA expression
tended to be higher in histologically more advanced
tumors (G2 and G3 of histological grading). Such finding
is in line with the results presented by Darb-Eshafani
et al., who observed that mTOR pathway activation was
more prevalent in high grade, high stage tumors [16].
Yoshida et al. reported on similar observation, which
indicated more pronounced p-mTOR expression in
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pression of phosphorylated mTOR and worse prognosis
[41]. Contrary to those findings, Choi et al. described
significantly decreased p-mTOR expression in deep infil-
trating endometrial tumors and indicated that expres-
sion of p-mTOR predicted better disease-free survival in
endometrial cancer patients [47]. No et al. reported on
infrequent mTOR expression (7.1%) in endometrial can-
cer and did not reveal any correlation between mTOR
expression and histological type, grade, stage, myome-
trial invasion, lymph node metastasis and survival in a
large group of 141 patients [48]. In opposition to those
observations Wahl et al. observed cytoplasmic p-mTOR
expression in 89.2% of type 1 endometrial carcinomas
and Mori et al. found moderate and strong expression of
phosphorylated mTOR in 81% of endometrioid endo-
metrial cancer samples [42,43]. Such discrepant findings
presented by different authors are difficult to interpret.
To some extent they could be explained by histological
heterogeneity of sample populations used in some of
those studies [48]. However, relations between mTOR
kinase expression and EEC biology warrant further
evaluation and are particularly important in the context
of only moderate responses observed in endometrial
cancer patients treated with mTOR pathway inhibitors.
In our study increased level of mTOR mRNA was ac-
companied by down-regulation of miR-99a, miR-100
and miR-199b, which were found to target this gene in
the analysis performed using three in silico algorithms.
No previous study reported on the connection between
expression of those miRNAs and mTOR transcripts level
in endometrial cancer. However, miR-100 was found
strongly down-regulated in clear cell ovarian carcinoma
and its altered expression was associated with increased
expression of mTOR mRNA and protein. Moreover, a
direct link between miR-100 and mTOR expression was
proven experimentally in the same study. The authors
also found that the increase of intracellular miR-100
level enhanced therapeutic effect of mTOR inhibitor in
clear cell ovarian carcinoma cell line [49]. Li et al.
described down-regulation of miR-99a in hepatocellular
carcinoma, which was accompanied by increased expres-
sion of its two target genes mTOR and IGF1R. The
authors demonstrated, that transfection with miR-99a
resulted in mTOR pathway inhibition and cell cycle ar-
rest in that cancer [50]. Chen at al. obtained similar
results and observed down-regulation of both mTOR
and IGF1R after transfection with miR-99 family mem-
bers in head and neck squamous cell carcinoma [51]. A
connection between decreased expressions of miR-99a,
miR-99b and miR-100 and elevated level of mTOR was
also described in prostate cancer and was associated
with more advanced tumor stage [52]. Important role of
miR-199b-5p was found in medulloblastoma. Garziaet al. reported its lower expression in non-metastatic
versus metastatic medulloblastomas and observed that
over-expression of miR-199b-5p reduced proliferation of
medulloblstoma cells in vitro and depleted tumor
growth in vivo [53].
Although a number of studies reported alterations in
miRNAs expression in endometrial cancer only three
studies described down-regulation of miR-199b and
miR-99 family members [54-56]. Wu et al. compared
miRNA expression in ten EEC samples and ten match-
ing endometrial tissues and found decreased expression
of miR-99b [54]. Chung et al. reported down-regulation
of miR-199b and the fold change of its expression was
similar to the one observed in our study [56]. In the
study performed by Snowdon et al. the authors com-
pared normal endometrium, atypical hyperplasia (AH)
and EEC samples and found that expression of miR-100
and miR-199b was decreased both in AH and in EEC tis-
sues [55]. Moreover down-regulation of those miRNAs
was grater in EEC comparing to AH samples [55]. In
our study a correlation was found between higher histo-
logical grade and lower expression of miR-199b and
miR-99a. Although Snowdon at al. were not able to per-
form correlation analysis between histological grade and
clinical stage and miRNA expression due to the small
size of studied population, the difference between AH
and EEC groups indicated that expression of miR-100
and miR-199b tended to be higher in more advanced
stages of endometrial neoplasia [55].
Our study revealed that greater degree of miR-199b
and miR-99a down-regulation was attributed to high–
grade endometrial tumors. At the same time expression
of mTOR kinase mRNA was higher in more histologi-
cally advanced tumors, which further supported our hy-
pothesis on the connection between mTOR kinase and
studied miRNAs. In addition, there was a significant re-
verse correlation between expression of all three studied
miRNAs and mTOR mRNA expression in matched EEC
tissues.
In order to further evaluate the role of miR-99a,
miR-100 and miR-199b in EEC we assessed their ex-
pression in matched plasma samples obtained from the
same group of EEC patients. Surprisingly we found that
plasma expression levels of all studied miRNAs were
significantly increased in EEC patients in comparison
to healthy controls and that expression of miR-99a was
higher in patients with clinically more advanced dis-
ease. Although the discrepant expression of miR-99a,
miR-100 and miR-199b between EEC tissues and
plasma is difficult to explain at the time, it could be an
additional hallmark of this disease and warrants further
investigation. Discrepant expression of another miRNA
– miR-92a, was observed in tissue and plasma samples
obtained from patients with leukemia, lymphoma and
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formed by Tanaka et al. authors observed that miR-92a,
which was attributed oncogenic properties, was highly
increased in leukemic cells and down-regulated in the
plasma of leukemia patients. Authors hypothesized, that
apart from transcribing essential miRNAs, cancer cell
might specifically take in exosomes containing miR-92a
from the blood, which would result in observed de-
crease of that miRNA in plasma [57]. Ohyashiki et al.
reported similar discordant expression of miR-92a in
plasma and tumor tissues in non-Hodgkin’s lymphoma
[58]. Shigoka et al. also found that miR-92a was highly
up-regulated in tumors and significantly decreased in
plasma of hepatocellular carcinoma patients [59].
Another important aim of our study was to evaluate
diagnostic and prognostic values of miR-99a, miR-100
and miR-199b expression in tissues and plasma of EEC
patients. For this purpose we constructed ROC curves
and developed miRNA signatures, which could classify
cancer and control samples with high sensitivity and
specificity. The 3-miRNA tissue signature developed
using multivariate logistic regression was more accurate
in discriminating EEC samples in comparison to single
miRNAs. Utility of such signature could potentially fa-
cilitate diagnosis in poorly differentiated, disseminated
and metastatic tumors. Our study also revealed that the
2-miRNA plasma signature (miR-99a/miR-199b) was
very accurate in discriminating EEC samples with sensi-
tivity of 88% and specificity of 93%. Survival analysis
indicated that both miR-99a and miR-100 were signifi-
cantly associated with prognosis of overall survival and
were independent prognostic factors in a multivariate
analysis. One of the great challenges for performing
qPCR based miRNA expression analysis in tissues and
especially in plasma samples is to use proper normal-
ization strategy, which in most cases bases on reference
miRNAs or small RNAs. In the presented study normal-
ization was performed using carefully chosen endogen-
ous controls both for tissue and plasma analysis, which
increases validity of our results.
To our best knowledge only two previously published
studies attempted to evaluate diagnostic and prognostic
values of miRNA expression in endometrial cancer
tissues.
Corresponding with our results, Chung et al. reported
that expression of miR-199b yielded AUC value of 0.837
in detection of EEC tissue samples [56]. Cohn et al.
found that miR-199a was more commonly overexpressed
in a subset of patients who did not experience recur-
rence or death from the disease and its down-regulation
in endometrial cancer tissues correlated significantly
with shorter progression-free and overall survival [60].
Early diagnosis of endometrial cancer is of immense
importance as it facilitates radical surgical treatment andprevents the necessity of adjuvant therapy, which can be
connected with severe side effects. However, at present
no reliable screening strategy is available for this malig-
nancy. We suggest, that after proper validation tissue
and plasma miRNA signatures developed in the current
study could have a potential to be applied in a clinical
setting. Although plasma miRNA signature was highly
accurate in distinguishing between EEC and control
samples the number of samples used for its development
can limit the value of this finding. Therefore we are
planning to further investigate and validate our results
in a larger group of patients and in the context of other
gynecological pathologies.
Conclusions
We conclude that increased expression of mTOR kinase
in endometrioid endometrial cancer coexists with down-
regulation of its targeting miRNAs, miR-99a, miR-100
and miR-199b, which could suggest a new mechanism of
mTOR pathway activation in this malignancy. Although
functional studies are necessary to directly prove mTOR
regulation by studied miRNAs in EEC, presented results
along with studies performed in other tumors seem to
support this novel mechanism of altered mTOR kinase
pathway. In addition, our findings implicate that miR-
99a, miR-100 and miR-199b signatures are strongly asso-
ciated with the diagnosis of endometrioid endometrial
carcinoma and after validation in larger groups of
patients could be considered promising non-invasive
biomarkers for detection and prognosis of this cancer.
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